Skip to main content
. 2017 Mar 31;2017(3):CD008676. doi: 10.1002/14651858.CD008676.pub2

Hase 1998.

Study characteristics
Methods Trial design: parallel (3 arms ‐ 2 arms relevant to this review)
Location: military regiment, Halmstad, Sweden
Number of centres: 1
Study duration: recruitment period is not stated but the duration of rinsing was 6 months
Participants Participants: military conscripts and military staff (adult males) with gingivitis
Inclusion criteria: males aged at least 18 years; at least 25% bleeding sites of all gingival sites (6 sites per tooth) on BOP using a Florida‐probe with a pressure of 0.25 N to the bottom of the pocket; minimum 16 healthy teeth without crowns, bridge‐work, or ill‐fitting dental restorations
Exclusion criteria: 4 or more teeth with cavities or pocket probing depth 5 mm or more; previous hypersensitive reactions to drugs; alcohol or drug addiction; severe liver or renal disease; psychiatric disorders; severe disability with multiple drug therapy; receiving antibiotics within 6 weeks of the prestudy visit; antiphlogistics (including sprays with corticosteroids) or anticholinergic drugs such as antiparkinson drugs or antidepressants
Baseline gingivitis: (% sites BOP) Gp A: mean 42.7 (SE 2.7); Gp B: mean 47.3 (SE 2.6); Gp C: mean 43.9 (SE 2.7) (unpublished data)
Age at baseline (years): Gp A: mean 24 (SD 10); Gp B: mean 26 (SD 7); Gp C: mean 23 (SD 7)
Gender: males only
Number randomised: 140 (Table 2 page 748) (Gp A: 47; Gp B: 48; Gp C: 45)
Number evaluated (per protocol analysis): 100 (Gp A: 30; Gp B: 37; Gp C: 33)
Interventions Comparison: CHX digluconate rinse versus delmopinol hydrochloride rinse* versus placebo rinse
Gp A (n = 47): CHX (0.2% Hibitane Dental), 10 mL, 1 min, twice daily
*Gp B (n = 48): delmopinol hydrochloride (0.2%), same routine. We excluded this arm from our risk of bias and analysis
Gp C (n = 45): same routine using placebo (same as Gp B but without delmopinol and sodium hydroxide)
Prophylaxis at baseline: supra‐ and subgingival scaling
OHI: participants were instructed not to change their normal mechanical tooth cleaning methods during the study
Partly supervised rinsing (mostly supervised but occasionally unsupervised due to military training)
Timing of rinsing in relation to toothbrushing: after toothbrushing
Postrinsing instructions: not reported
Outcomes Gingivitis (gingival BOP using a Florida‐probe with a pressure of 0.25 N to the bottom of the pocket (Gibbs 1988, Löe 1967)), measured at 3 and 6 months
Plaque (PI, TQH, Turesky 1970) measured at 3 and 6 months
Calculus (Volpe‐Manhold Calculus Index, Volpe 1967), measured at 3 and 6 months
Extrinsic tooth staining (Staining Index of Shaw & Murray 1977), measured at 3 and 6 months
Adverse events (transient anaesthetic sensation, taste modification, staining (teeth or tongue or both)) were recorded
Microbiological monitoring of plaque and salivary microflora was performed during the treatment period and also 3 months after the end of treatment for 65 patients ‐ results (excluding BOP which is presented here) presented separately ‐ not relevant to this review
Funding Not reported
Notes Sample size calculation: based on BOP. The standard deviation was estimated to 14 and a difference of 10% units between placebo and delmopinol was considered worth detecting. Based on a power of 95% at significance level of 5%, 50 participants per group were required. Therefore this was not achieved
Adverse effects: transient anaesthetic sensation in the oral mucosa especially at the tip of the tongue in delmopinol and CHX groups reached the same level of reporting at 6 months. Taste modification was commonly reported in both the delmopinol and CHX groups. Staining of teeth or tongue was common in the CHX group
Adverse effects at 6 months (Table 4) (% participants experiencing the adverse effect):
local anaesthesia/hypoasthesia/parasthesia CHX 18%, placebo 0%, delmopinol
22%; taste loss/taste perversion: CHX 16%, placebo 0%, delmopinol 24%; discolouration teeth/discolouration tongue: CHX 13%, placebo 7%, delmopinol 8%
Declarations/conflicts of interest: nothing explicitly stated but first author was employee of Biosurface AB, Malmo, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Quote: "Patients were allocated to treatment groups according to a computer‐generated randomisation list, where treatment was balanced within blocks of 6 patients"
Comment: adequate method of random sequence generation
Allocation concealment (selection bias) Unclear risk Quote: "Packaging and labelling were carried out at an independent Clinical Service Department"
Comment: it is not clear whether the assignment of subjects to groups was carried out at the independent Clinical Service Department
Blinding of participants and personnel (performance bias)
All outcomes High risk The study is reported to be "double‐blind" and "The various test solutions were dispensed in identical 200 ml amber glass bottles." The placebo was the same composition as the delmopinol rinse but without the delmopinol and sodium hydroxide. It is unclear who supervised the rinsing and if they were blinded to allocation of the rinse
Comment: the higher level of staining of the teeth and tongue in the CHX group (plus greater taste modification and transient anaesthetic sensation in the active groups) meant that participants could have worked out which group they were in and this could have affected their oral health behaviours and hence the outcomes. The direction of this potential bias is not clear
Blinding of outcome assessment (detection bias)
All outcomes High risk The study is reported to be "double‐blind". Assessments were made by 5 trained dental hygienists who followed the same subjects throughout the treatment period
Comment: the authors do not report precisely who was blinded, but even if this includes the outcomes assessors the higher level of staining of the teeth and tongue in the CHX group meant that they could not be adequately blinded and this could have affected the outcome assessment. The direction of this potential bias is not clear
Incomplete outcome data (attrition bias)
All outcomes High risk At 6 months 29 participants are excluded from the analysis in the study arms of interest to this review but only 16 are reported as withdrawn from the study with reasons for withdrawal. Data presented here for loss to follow‐up are based on the total lost to follow‐up (n = 29)
Attrition at 6 months 29/92 (31.5%). By group: CHX 17/47 (36.2%), placebo 12/45 (26.7%). Reasons for loss to follow‐up: CHX: adverse events/lack of cooperation, release from military service; placebo: adverse events/lack of cooperation, release from military service, moved away
Comment: very high attrition which may be related to type of mouthrinse and could feasibly introduce bias in the results
Selective reporting (reporting bias) Low risk Information on means and SEs are presented graphically. From correspondence with the author, additional information was obtained on means and SEs which enabled calculation of SDs from SEs and inclusion of these data in the meta‐analyses
Other bias Unclear risk Assessments were made by 5 trained dental hygienists who followed the same subjects throughout the treatment period. A calibration session for all assessments was performed before the start of treatment but the results of the calibration (Inter‐ and intraexaminer reliability) are not reported
Mean age was balanced across groups at baseline. No statistically significant demographic differences between the groups were recorded. Baseline BOP and mean plaque scores appear balanced but the statistical significance of the differences is not reported